- Home
- OI vs SUPN Comparison
OI vs SUPN Comparison
Compare OI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OI
- SUPN
- Stock Information
- Founded
- OI 1903
- SUPN 2005
- Country
- OI United States
- SUPN United States
- Employees
- OI N/A
- SUPN N/A
- Industry
- OI Containers/Packaging
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- OI Consumer Discretionary
- SUPN Health Care
- Exchange
- OI Nasdaq
- SUPN Nasdaq
- Market Cap
- OI 1.6B
- SUPN 1.9B
- IPO Year
- OI N/A
- SUPN 2012
- Fundamental
- Price
- OI $10.75
- SUPN $36.43
- Analyst Decision
- OI Buy
- SUPN Hold
- Analyst Count
- OI 8
- SUPN 1
- Target Price
- OI $16.25
- SUPN $36.00
- AVG Volume (30 Days)
- OI 1.5M
- SUPN 348.4K
- Earning Date
- OI 02-04-2025
- SUPN 02-25-2025
- Dividend Yield
- OI N/A
- SUPN N/A
- EPS Growth
- OI N/A
- SUPN 130.79
- EPS
- OI N/A
- SUPN 1.07
- Revenue
- OI $6,643,000,000.00
- SUPN $651,972,000.00
- Revenue This Year
- OI N/A
- SUPN $7.82
- Revenue Next Year
- OI N/A
- SUPN N/A
- P/E Ratio
- OI N/A
- SUPN $34.05
- Revenue Growth
- OI N/A
- SUPN 6.79
- 52 Week Low
- OI $9.85
- SUPN $25.53
- 52 Week High
- OI $17.58
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- OI 41.60
- SUPN 52.26
- Support Level
- OI $10.03
- SUPN $35.73
- Resistance Level
- OI $10.39
- SUPN $37.34
- Average True Range (ATR)
- OI 0.45
- SUPN 1.20
- MACD
- OI 0.04
- SUPN -0.01
- Stochastic Oscillator
- OI 44.33
- SUPN 69.02
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.